Atypical Hemolytic Uremic Syndrome: all 45 studies
Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Ravulizumab Outcomes in Polish Patients With aHUSRecruitingNCT07399730
- Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUSRecruitingNCT07308574Phase 4
- Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecruitingNCT06312644
- National Registry of Rare Kidney DiseasesRecruitingNCT06065852
- Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare DiseasesRecruitingNCT05996731Not applicable
- Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)RecruitingNCT05935215Phase 3
- Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized TherapyRecruitingNCT05805202Not applicable
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingNCT05795140Phase 3
- Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic SyndromeRecruitingNCT05726916Phase 3
- Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic MicroangiopathyNot yet recruitingNCT05684159Phase 2
- Complement Prospective Evaluation of Thrombotic Microangiopathy on EndotheliumRecruitingNCT04745195
- OMS721 Compassionate Use in Patients With Thrombotic MicroangiopathyAvailableNCT02355782
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT01793168
- Atypical Hemolytic-Uremic Syndrome (aHUS) RegistryRecruitingNCT01522183
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active, not recruitingNCT04958265Phase 3Results posted
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active, not recruitingNCT04861259Phase 3Results posted
- Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsCompletedNCT03518203Phase 2Results posted
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromeTerminatedNCT03205995Phase 3Results posted
- Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT03131219Phase 3Results posted
- Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT02949128Phase 3Results posted
- Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and TreatmentTerminatedNCT02614898Results posted
- Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesCompletedNCT02222545Phase 2Results posted
- An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic SyndromeCompletedNCT01194973Phase 2Results posted
- An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic SyndromeCompletedNCT01193348Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844844Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844545Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUSCompletedNCT00844428Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT00838513Phase 2Results posted
- The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in EgyptCompletedNCT07218536
- A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome PatientsActive, not recruitingNCT06099236
- A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant MedicationsCompletedNCT06004947Phase 1
- Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedNCT04889430Phase 3
- Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)CompletedNCT04859608Phase 3
- Observational Study of Elizaria® in aHUS PatientsCompletedNCT04749810
- Eculizumab to Cemdisiran Switch in aHUSWithdrawnNCT03999840Phase 2
- TTP and aHUS in Complicated PregnanciesStatus unknownNCT03605511
- Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case SeriesStatus unknownNCT03574506
- A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeWithdrawnNCT03303313Phase 2
- The Role of Microparticles as a BiomarkerWithdrawnNCT02626663
- Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUSCompletedNCT02574403Phase 4
- Complement Inhibition in aHUS Dialysis PatientsTerminatedNCT02464891Phase 2
- A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT01770951
- The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT01757431Phase 2
- To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS PatientsCompletedNCT01755429
- aHUS Observational Long Term Follow-UpTerminatedNCT01522170